先聲藥業(2096.HK)大漲超18% 股價創近半年新高
格隆匯1月17日丨繼上週五漲超6%後,先聲藥業(2096.HK)今日盤中再度大漲,一度大漲超18%至11.48港元,股價創去年7月以來新高,市值超300億港元。消息面上,先聲藥業今日宣佈任命周高波先生為首席投資官,負責公司創新藥投資和合作業務的拓展、新投資平台建設以及戰略規劃與實踐,今日正式上任。另外,先聲藥業12日宣佈自主研發“合成致死”抗腫瘤創新機制口服蛋白精氨酸甲基轉移酶5(PRMT5)抑制劑(項目號:SIM0272,產品代號:SCR-6920)向國家藥品監督管理局遞交晚期惡性腫瘤治療的臨牀試驗申請獲受理。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.